Piper Sandler analyst Adam Maeder lowered the firm’s price target on RxSight (RXST) to $10 from $11 and keeps a Neutral rating on the shares. The firm notes the company reported Q4 top-line results that came in-line with its preliminary announcement. RxSight announced full year 2026 revenue guidance of $120M-$135M, which came in below estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST: